BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 8612303)

  • 21. Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumors.
    Rafi I; Boddy AV; Calvete JA; Taylor GA; Newell DR; Bailey NP; Lind MJ; Green M; Hines J; Johnstone A; Clendeninn N; Calvert AH
    J Clin Oncol; 1998 Mar; 16(3):1131-41. PubMed ID: 9508200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective delivery of CB300638, a cyclopenta[g]quinazoline-based thymidylate synthase inhibitor into human tumor cell lines overexpressing the alpha-isoform of the folate receptor.
    Theti DS; Bavetsias V; Skelton LA; Titley J; Gibbs D; Jansen G; Jackman AL
    Cancer Res; 2003 Jul; 63(13):3612-8. PubMed ID: 12839949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administration.
    Jodrell DI; Bowman A; Rye R; Byrne B; Boddy A; Rafi I; Taylor GA; Johnston A; Clendeninn NJ
    Br J Cancer; 1999 Feb; 79(5-6):915-20. PubMed ID: 10070890
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design and synthesis of potent non-polyglutamatable quinazoline antifolate thymidylate synthase inhibitors.
    Marsham PR; Wardleworth JM; Boyle FT; Hennequin LF; Kimbell R; Brown M; Jackman AL
    J Med Chem; 1999 Sep; 42(19):3809-20. PubMed ID: 10508430
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583).
    Jackman AL; Newell DR; Gibson W; Jodrell DI; Taylor GA; Bishop JA; Hughes LR; Calvert AH
    Biochem Pharmacol; 1991 Oct; 42(10):1885-95. PubMed ID: 1741766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
    Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
    Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thymidylate synthase inhibitors.
    Touroutoglou N; Pazdur R
    Clin Cancer Res; 1996 Feb; 2(2):227-43. PubMed ID: 9816165
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in normal and tumor cell lines and tissues.
    Welsh SJ; Titley J; Brunton L; Valenti M; Monaghan P; Jackman AL; Aherne GW
    Clin Cancer Res; 2000 Jun; 6(6):2538-46. PubMed ID: 10873110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determination of absorption characteristics of AG337, a novel thymidylate synthase inhibitor, using a perfused rat intestinal model.
    Hu M; Roland K; Ge L; Chen J; Li Y; Tyle P; Roy S
    J Pharm Sci; 1998 Jul; 87(7):886-90. PubMed ID: 9649359
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulation of anti-metabolite effects. Effects of thymidine on the efficacy of the quinazoline-based thymidylate synthetase inhibitor, CB3717.
    Jackman AL; Taylor GA; Calvert AH; Harrap KR
    Biochem Pharmacol; 1984 Oct; 33(20):3269-75. PubMed ID: 6487375
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thymidylate synthase inhibitors.
    Danenberg PV; Malli H; Swenson S
    Semin Oncol; 1999 Dec; 26(6):621-31. PubMed ID: 10606255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quinazoline thymidylate synthase inhibitors: methods for assessing the contribution of polyglutamation to their in vitro activity.
    Jackman AL; Kimbell R; Brown M; Brunton L; Boyle FT
    Anticancer Drug Des; 1995 Oct; 10(7):555-72. PubMed ID: 7495479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cross-resistance to antifolates in multidrug resistant cell lines with P-glycoprotein or multidrug resistance protein expression.
    van Triest B; Pinedo HM; Telleman F; van der Wilt CL; Jansen G; Peters GJ
    Biochem Pharmacol; 1997 Jun; 53(12):1855-66. PubMed ID: 9256160
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quinazoline antifolates inhibiting thymidylate synthase: 2-desamino derivatives with enhanced solubility and potency.
    Jones TR; Thornton TJ; Flinn A; Jackman AL; Newell DR; Calvert AH
    J Med Chem; 1989 Apr; 32(4):847-52. PubMed ID: 2704030
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms of action of FdUMP[10]: metabolite activation and thymidylate synthase inhibition.
    Bijnsdorp IV; Comijn EM; Padron JM; Gmeiner WH; Peters GJ
    Oncol Rep; 2007 Jul; 18(1):287-91. PubMed ID: 17549381
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activity of the thymidylate synthase inhibitor 2-desamino-N10-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in L1210 in vivo.
    Jackman AL; Taylor GA; O'Connor BM; Bishop JA; Moran RG; Calvert AH
    Cancer Res; 1990 Sep; 50(17):5212-8. PubMed ID: 2386929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells.
    Mauritz R; Bekkenk MW; Rots MG; Pieters R; Mini E; van Zantwijk CH; Veerman AJ; Peters GJ; Jansen G
    Clin Cancer Res; 1998 Oct; 4(10):2399-410. PubMed ID: 9796971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and synthesis of Cyclopenta[g]quinazoline-based antifolates as inhibitors of thymidylate synthase and potential antitumor agents(,).
    Bavetsias V; Marriott JH; Melin C; Kimbell R; Matusiak ZS; Boyle FT; Jackman AL
    J Med Chem; 2000 May; 43(10):1910-26. PubMed ID: 10821704
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased thymidylate synthase in L1210 cells possessing acquired resistance to N10-propargyl-5,8-dideazafolic acid (CB3717): development, characterization, and cross-resistance studies.
    Jackman AL; Alison DL; Calvert AH; Harrap KR
    Cancer Res; 1986 Jun; 46(6):2810-5. PubMed ID: 2938731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates.
    Backus HH; Pinedo HM; Wouters D; PadrĂ³n JM; Molders N; van Der Wilt CL; van Groeningen CJ; Jansen G; Peters GJ
    Int J Cancer; 2000 Sep; 87(6):771-8. PubMed ID: 10956384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.